Iconovo AB (OSTO:ICO) Notes Receivable: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ICO Iconovo AB OSTO:ICO
34 GF Score
Price kr1.08
GF Value kr0.27
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Iconovo AB Notes Receivable?

Iconovo AB OSTO:ICO -0.92% 34 Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:ICO with a GF Score™ of 34/100 and a GF Value™ of kr0.27 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Iconovo AB's Notes Receivable for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Iconovo AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for Iconovo AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iconovo AB Notes Receivable Chart

Iconovo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Iconovo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ICO
34GF Score
Iconovo AB OSTO:ICO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iconovo AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.00 Mil mean?
Iconovo AB (OSTO:ICO) has a Notes Receivable of kr0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Iconovo AB and its competitors.
Is Iconovo AB's Notes Receivable too high?
Iconovo AB's current Notes Receivable is kr0.00 Mil. Overall, Iconovo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's Notes Receivable compare to ABT and SYK?
Iconovo AB's Notes Receivable of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Iconovo AB and its competitors. Iconovo AB's current Notes Receivable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.27, compared to a current price of kr1.08 — trading 300% above its estimated fair value. The current Notes Receivable is kr0.00 Mil. Iconovo AB's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iconovo AB (OSTO:ICO) Overvalued in 2026?

Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued. The current stock price of kr1.08 is trading 300% above its estimated GF Value™ of kr0.27. GuruFocus considers Iconovo AB to be Significantly Overvalued.

Key valuation signals for OSTO:ICO:

  • Notes Receivable: kr0.00 Mil
  • GF Value™: kr0.27 vs. price of kr1.08 (300% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iconovo AB Business Description

Address Ideongatan 3 A-B, Delta 6, Lund, SWE, SE-223 62
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
34GF Score

Get the complete analysis for OSTO:ICO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.08
Price
kr0.27
GF Value